Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
The company operates four mid-sized hospitals with a total bed capacity of 556 in eastern India
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
It works by collecting aerosols and identifies the presence of dangerous pathogens using sensitive, specific and rapid detection in near-real time without laboratory analysis
In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The Pune centre expands its presence beyond Bangalore and Hyderabad
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Subscribe To Our Newsletter & Stay Updated